Table 1.
Demographic and clinical characteristics of subjects with FEP and HC subjectsa
| FEP‐AH [PANSS P3 ≥ 4] (n = 27) | FEP‐NAH [PANSS P3 ≤ 2] (n = 24) | HC (n = 96) | Statistics | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristics | Mean | SD | Mean | SD | Mean | SD | χ2/T/F | df | P value |
| Age (years)b | 22.48 | 4.95 | 22.69 | 5.12 | 24.07 | 4.84 | 1.167 | 144 | 0.314 |
| Sex (Male/Female)a | 9/18 | 12/12 | 57/39 | 5.846 | 2 | 0.054 | |||
| Years of Education (years)b, c | 12.85 | 1.97 | 13.92 | 1.94 | 14.36 | 1.69 | 7.66 | 143 | <0.001d |
| IQb | 97.33 | 14.25 | 100.29 | 11.64 | 111.76 | 10.62 | 21.74 | 144 | <0.001d, e |
| Socio‐Economic Status of Parentsb, f | 2.63 | 0.84 | 2.58 | 0.97 | 2.81 | 0.88 | 0.85 | 137 | 0.43 |
| Age at Onset (years)g | 22 | 4.97 | 23.54 | 4.45 | −1.169 | 48.99 | 0.248 | ||
| Duration of Illness (years)g | 0.6 | 0.52 | 0.73 | 0.47 | −0.888 | 48.97 | 0.379 | ||
| Duration of Antipsychotics Usage Before MRI scanning (years)g | 0.09 | 0.16 | 0.18 | 0.23 | −1.576 | 40.31 | 0.123 | ||
| Antipsychotics Treatment at MRI Scanning (CPZ equivalent, mg/day)g | 327.47 | 522.24 | 238.02 | 225.96 | 0.809 | 36.28 | 0.424 | ||
| Positive and negative symptom scale for schizophrenia (PANSS)g | |||||||||
| Positive symptom factor score (P1, P3, P5‐6, N7, G1, G9, G12) | 22.81 | 5.42 | 16.96 | 4.76 | 4.108 | 49 | <.001 | ||
| Negative symptom factor score (N1‐4, N6‐7, G16) | 18.81 | 6.02 | 16.58 | 4.84 | 1.466 | 48.54 | .149 | ||
| Disorganized symptom factor score (P2, N5, G5, G10‐11, G13, G15) | 15.3 | 4.8 | 12.33 | 3.71 | 2.479 | 48.13 | .017 | ||
| Total score | 73.0 | 13.90 | 59.71 | 12.78 | 3.556 | 48.94 | <.001 | ||
| HAM‐Dg | 10.19 | 3.54 | 9.88 | 5.74 | 0.229 | 37.43 | .82 | ||
| HAM‐Ag | 8.59 | 4.43 | 7.33 | 3.84 | 1.087 | 48.97 | .282 | ||
| Modified GAF‐Mg | |||||||||
| At Intake | 41.67 | 8.59 | 51.63 | 10.45 | −3.691 | 44.68 | <.001 | ||
| One Year Prior to Intake | 67.7 | 12.27 | 72.04 | 10.74 | −1.346 | 48.99 | .184 | ||
Abbreviations: AH, auditory hallucination; CPZ, Chlorpromazine; FEP, first‐episode psychosis; MRI, magnetic resonance imaging.
a
Differences between variables of three groups were assessed using chi‐squared test.
b
Differences between variables of three groups were assessed using analysis of variance test.
c
For 1 case of HC, information was missing.
d
Statistically significant group difference between FEP‐AH versus HC (p < .05).
e
Statistically significant group difference between FEP‐NAH versus HC (p < .05).
f
For seven cases of HC, information was missing.
g
Differences between variables of two groups were assessed using independent t‐test.